Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals develops clinical-stage therapies for addiction and related disorders, with its lead investigational product candidate, AD04, focused on alcohol use disorder in heavy drinking patients. News about ADIL commonly centers on AD04 clinical-development planning, FDA-related regulatory discussions, precision-medicine positioning, intellectual property filings, manufacturing and technical-transfer work, and potential commercial pathways for the program.
Company updates also cover financial results, cash runway commentary, Nasdaq listing compliance, and governance or capital-structure actions tied to its public-company status. The recurring business context is a single-segment biopharmaceutical developer advancing a genetically targeted serotonin-3 receptor antagonist approach for alcohol use disorder.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) is set to report topline results from its ONWARD™ Phase 3 clinical trial on July 20, 2022. The trial assesses the efficacy and safety of AD04 in treating Alcohol Use Disorder in genetically screened patients. Conducted across 25 sites in six countries, it includes heavy and very heavy drinkers. Previous Phase 2b results indicated significant reductions in drinking frequency and quantity without serious safety concerns. The ongoing research may expand to other addictive disorders, highlighting the drug's potential impact.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced the database lock for its ONWARD™ Phase 3 trial, which is crucial for evaluating the efficacy of AD04 in treating Alcohol Use Disorder (AUD). With data now set, professional statisticians will analyze the results, with top-line findings expected by mid-July 2022. The ONWARD trial involves patients genetically screened for specific polymorphisms and is pivotal for FDA approval of AD04. Adial emphasizes the importance of its research in addiction medicine, reflecting a strong commitment to advancing treatment options.
Adial Pharmaceuticals has locked the database for its ONWARD Phase 3 clinical trial and transferred the data to independent statistical consultants for analysis. Results are expected to be announced in July 2022. The trial aims to evaluate the efficacy and safety of AD04 in reducing heavy drinking days among patients with Alcohol Use Disorder. Notably, no drug-related serious adverse events were reported. ONWARD is crucial for potential regulatory approval of AD04 based on targeted genetic screening of patients, paving the way for treatment options in alcohol addiction.
Adial Pharmaceuticals announced the issuance of patent number 11,351,154 on June 7, 2022, covering a genetic diagnostic panel linked to its lead product, AD04, aimed at treating Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD). This patent enhances their intellectual property portfolio, now exceeding 90 patents worldwide, ensuring market protection until at least 2031. With an estimated 35 million individuals in the U.S. suffering from AUD, the company anticipates significant opportunities in both AD04 and its diagnostic test. Results from the pivotal ONWARD Phase 3 trial are expected soon.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced a research collaboration between its subsidiary, Purnovate, and the Medical College of Wisconsin. The focus is on developing adenosine analogs as treatments for diabetes and non-alcoholic steatohepatitis (NASH). The collaboration aims to test Purnovate's compounds in preclinical models, which could potentially address significant unmet medical needs. The global NASH market is projected to exceed $54 billion by 2027, highlighting the potential market impact of these developments.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) is nearing the completion of its ONWARD™ Phase 3 trial for AD04, aimed at treating Alcohol Use Disorder (AUD), with results expected this quarter. The company ended Q1 2022 with a cash balance of $12.7 million, up from $6.1 million in Q4 2021. R&D expenses dropped to $0.6 million, and net loss improved to $2.9 million. With AUD representing a $36 billion U.S. market and 35 million affected individuals, Adial plans to advance discussions for potential commercialization of AD04, which is designed for easy oral administration.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) has announced a collaboration with UC San Diego to explore its adenosine analogs for treating inflammatory bowel disease (IBD). This partnership aims to validate the therapeutic potential of Purnovate’s compounds in preclinical models of IBD, conditions such as Crohn's disease, and ulcerative colitis. The global IBD treatment market is projected to reach USD 27.8 billion by 2028, indicating significant unmet medical needs. Adial's CEO expresses optimism about their compounds addressing IBD and other inflammatory conditions.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) will have CEO William Stilley participate in the 2022 Virtual Growth Conference from March 28-30. The event, hosted by Maxim Group LLC and M-Vest, requires prior membership to attend. Stilley's pre-recorded corporate update will be accessible throughout the conference. This event will feature presentations from various sectors, including Biotech and Healthcare. Adial is focused on developing treatments for addiction, with its lead drug AD04 currently in a pivotal Phase 3 trial for Alcohol Use Disorder.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced the completion of patient enrollment in its ONWARD™ Phase 3 trial, focusing on AD04 for treating Alcohol Use Disorder (AUD). The trial included 302 participants across 25 sites in Europe, surpassing initial targets. The CEO highlighted the significance of this milestone, emphasizing the need for effective AUD treatments amid rising public health concerns. Topline results are expected in Q2, aiming to demonstrate a statistically significant reduction in heavy drinking days for those treated with AD04 compared to a placebo.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) has successfully closed a registered direct offering, generating around $10 million. A single accredited institutional investor purchased approximately 2,322,250 shares of common stock, along with pre-funded warrants and additional warrants to acquire about 3,977,888 shares. The effective purchase price was $2.40 per share/warrant. The net proceeds will enhance Adial's balance sheet as it advances its Phase 3 ONWARD™ trial for AD04, targeting addiction treatments.